Cardiac POC Testing Devices Market, By Product Type, By End user, By Geography

Cardiac POC Testing Devices Market is estimated to be valued at USD 3,903.3 Mn in 2026 and is expected to reach USD 6,307.7 Mn by 2033, growing at a compound annual growth rate (CAGR) of 7.1% from 2026 to 2033.

Cardiac POC testing is a test performed for the diagnosis of heart disorders. POC or Point-of-care testing, also referred to as bedside test, is a diagnostic test at the point or position of care at the same place and time of patient care. Cardiac POC testing is a simple blood test that includes cholesterol and coagulation testing. Coagulation testing helps physicians examine the risk of developing thrombosis, clotting and bleeding inside blood vessels in the body, including the heart. Cardiac POC tests include Troponin, Creatine Kinase MB Isoenzyme s, and Brain Natriuretic Peptide (BNP) analysis, which are mainly employed to identify cardiovascular ailments such as, heart failure, myocardial infarction, and coronary syndromes. Cardiac POC testing device help to detect enzymes that are released at some point in heart failure and in vital cardiac conditions such as lactate dehydrogenase isoenzymes, brain Natriuretic Peptide s, kinase, and synthesizing Troponin.

Market Dynamics

The market for cardiac POC testing devices is gaining significant traction due to rising prevalence of cardiac disorders. According to World Health Organizations (WHO), 2011, around 8 million people suffered from coronary and peripheral heart diseases, which recorded the major cause of all the deaths, accounting for around 44% of total deaths in the U.S. Technological innovations and developments of cardiac POC testing devices are contributing to the market growth. For instance, the FDA approval of Firmware software in August 2017, launched by Abbott Laboratories is embedded in the hardware of a cardiac testing device. With this device, the cardiac rhythm can be easily monitored as well as control for the people at high-risk. However, lack of operating knowledge and economic instability in emerging economies are the factors restraining the market growth.

Market Taxonomy

This report segments the global cardiac POC testing device market on the basis of product type, end user, and geography. On the basis of product type, the cardiac POC testing device market is segmented into cardiac markers test and analyzers. The cardiac markers test is further sub-segmented into cardiac Troponin (cTn) test, myoglobin test, Creatine Kinase MB Isoenzyme (CK-MB) test, combinational test kits, and brain natriuretic peptide (BNP) test. On the basis of end-user, the cardiac POC testing device market is segmented into research laboratories, hospitals, ambulatory surgical centers, diagnostic laboratories, and others. For comprehensive understanding of market dynamics, the global cardiac POC testing device market is analyzed across key geographical regions namely, North America, Europe, Asia Pacific, Latin America, Africa, and Middle East. Each of these regions is analyzed on basis of market findings across major countries in these regions for a macro-level understanding of the market.

Key features of the study:

• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players.
• It profiles leading players in the global cardiac POC testing device market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans.
• Key companies covered as a part of this study include Abbott Laboratories, Siemens Healthineers, BG Medicine Inc., Roche Diagnostics, Nexus-Dx, LifeSign LLC., and Medtronic Inc.
• Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, end user upgrades, market expansion, and marketing tactics
• The global cardiac POC testing devices market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors and suppliers for Cardiac POC testing Device market, research and consulting firms, new entrants and financial analysts
• Various strategy matrices used in analyzing the cardiac POC testing devices market would provide stakeholders vital inputs to make strategic decisions accordingly

Market Segmentation

• By Product Type (Revenue, USD Mn, 2021-2033)
  • Cardiac Markers Test
  • Analyzers
• By End User (Revenue, USD Mn, 2021-2033)
  • Research Laboratories
  • Hospitals
  • Ambulatory Surgical Centers
  • Diagnostic Laboratories
  • Others
• By Region (Revenue, USD Mn, 2021-2033)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • Central Africa
  • North Africa
• Key Players
  • Abbott Laboratories
  • BG Medicine Inc.
  • Roche Diagnostics, Inc.
  • Medtronic Inc.
  • Siemens Healthineers